Integrated therapist and online CBT for depression in primary care (INTERACT): study protocol for a multi-centre randomised controlled trial.

Acceptability Blended treatment Cognitive behavioural therapy Depression Integrated cognitive behavioural therapy Internet-based treatment Primary care Qualitative research Randomised controlled trial

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
20 Jun 2023
Historique:
received: 30 03 2023
accepted: 19 05 2023
medline: 22 6 2023
pubmed: 21 6 2023
entrez: 20 6 2023
Statut: epublish

Résumé

Cognitive behavioural therapy (CBT) is an effective treatment for depression. Self-directed online CBT interventions have made CBT more accessible at a lower cost. However, adherence is often poor and, in the absence of therapist support, effects are modest and short-term. Delivering CBT online using instant messaging is clinically and cost-effective; however, most existing platforms are limited to instant messaging sessions, without the support of between-session "homework" activities. The INTERACT intervention integrates online CBT materials and 'high-intensity' therapist-led CBT, delivered remotely in real-time. The INTERACT trial will evaluate this novel integration in terms of clinical and cost-effectiveness, and acceptability to therapists and clients. Pragmatic, two parallel-group multi-centre individually randomised controlled trial, with 434 patients recruited from primary care practices in Bristol, London and York. Participants with depression will be identified via General Practitioner record searches and direct referrals. aged ≥ 18 years; score ≥ 14 on Beck Depression Inventory (BDI-II); meeting International Classification of Diseases (ICD-10) criteria for depression. alcohol or substance dependency in the past year; bipolar disorder; schizophrenia; psychosis; dementia; currently under psychiatric care for depression (including those referred but not yet seen); cannot complete questionnaires unaided or requires an interpreter; currently receiving CBT/other psychotherapy; received high-intensity CBT in the past four years; participating in another intervention trial; unwilling/unable to receive CBT via computer/laptop/smartphone. Eligible participants will be randomised to integrated CBT or usual care. Integrated CBT utilises the standard Beckian intervention for depression and comprises nine live therapist-led sessions, with (up to) a further three if clinically appropriate. The first session is 60-90 min via videocall, with subsequent 50-min sessions delivered online, using instant messaging. Participants allocated integrated CBT can access integrated online CBT resources (worksheets/information sheets/videos) within and between sessions. Outcome assessments at 3-, 6-, 9- and 12-month post-randomisation. The primary outcome is the Beck Depression Inventory (BDI-II) score at 6 months (as a continuous variable). A nested qualitative study and health economic evaluation will be conducted. If clinically and cost-effective, this model of integrated CBT could be introduced into existing psychological services, increasing access to, and equity of, CBT provision. ISRCTN, ISRCTN13112900. Registered on 11/11/2020. Currently recruiting participants. Trial registration data are presented in Table 1.

Sections du résumé

BACKGROUND BACKGROUND
Cognitive behavioural therapy (CBT) is an effective treatment for depression. Self-directed online CBT interventions have made CBT more accessible at a lower cost. However, adherence is often poor and, in the absence of therapist support, effects are modest and short-term. Delivering CBT online using instant messaging is clinically and cost-effective; however, most existing platforms are limited to instant messaging sessions, without the support of between-session "homework" activities. The INTERACT intervention integrates online CBT materials and 'high-intensity' therapist-led CBT, delivered remotely in real-time. The INTERACT trial will evaluate this novel integration in terms of clinical and cost-effectiveness, and acceptability to therapists and clients.
METHODS METHODS
Pragmatic, two parallel-group multi-centre individually randomised controlled trial, with 434 patients recruited from primary care practices in Bristol, London and York. Participants with depression will be identified via General Practitioner record searches and direct referrals.
INCLUSION CRITERIA METHODS
aged ≥ 18 years; score ≥ 14 on Beck Depression Inventory (BDI-II); meeting International Classification of Diseases (ICD-10) criteria for depression.
EXCLUSION CRITERIA METHODS
alcohol or substance dependency in the past year; bipolar disorder; schizophrenia; psychosis; dementia; currently under psychiatric care for depression (including those referred but not yet seen); cannot complete questionnaires unaided or requires an interpreter; currently receiving CBT/other psychotherapy; received high-intensity CBT in the past four years; participating in another intervention trial; unwilling/unable to receive CBT via computer/laptop/smartphone. Eligible participants will be randomised to integrated CBT or usual care. Integrated CBT utilises the standard Beckian intervention for depression and comprises nine live therapist-led sessions, with (up to) a further three if clinically appropriate. The first session is 60-90 min via videocall, with subsequent 50-min sessions delivered online, using instant messaging. Participants allocated integrated CBT can access integrated online CBT resources (worksheets/information sheets/videos) within and between sessions. Outcome assessments at 3-, 6-, 9- and 12-month post-randomisation. The primary outcome is the Beck Depression Inventory (BDI-II) score at 6 months (as a continuous variable). A nested qualitative study and health economic evaluation will be conducted.
DISCUSSION CONCLUSIONS
If clinically and cost-effective, this model of integrated CBT could be introduced into existing psychological services, increasing access to, and equity of, CBT provision.
TRIAL REGISTRATION BACKGROUND
ISRCTN, ISRCTN13112900. Registered on 11/11/2020. Currently recruiting participants. Trial registration data are presented in Table 1.

Identifiants

pubmed: 37340500
doi: 10.1186/s13063-023-07396-9
pii: 10.1186/s13063-023-07396-9
pmc: PMC10283272
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

421

Subventions

Organisme : Programme Grants for Applied Research
ID : NIHR PGfAR RP-PG-0514-20012

Informations de copyright

© 2023. The Author(s).

Références

Lancet. 2013 Feb 2;381(9864):375-84
pubmed: 23219570
JMIR Ment Health. 2020 Sep 3;7(9):e15972
pubmed: 32880580
Clin Trials. 2005;2(2):152-62
pubmed: 16279137
Br J Clin Psychol. 2013 Nov;52(4):347-64
pubmed: 24117909
Clin Psychol Rev. 2012 Jun;32(4):329-42
pubmed: 22466510
BMJ. 2012 Jun 06;344:e2758
pubmed: 22674921
J Med Internet Res. 2018 Jun 06;20(6):e10120
pubmed: 29875087
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Cognit Ther Res. 2010 Oct;34(5):429-438
pubmed: 20930925
Psychol Med. 1992 May;22(2):465-86
pubmed: 1615114
Br J Psychiatry. 2003 Sep;183:228-32
pubmed: 12948996
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Value Health. 2020 Dec;23(12):1662-1670
pubmed: 33248522
J Epidemiol Community Health. 1994 Apr;48(2):207-10
pubmed: 8189180
Ann Intern Med. 2010 Jun 1;152(11):726-32
pubmed: 20335313
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
JMIR Ment Health. 2019 Jul 12;6(7):e12546
pubmed: 31301126
BMJ Open. 2017 Feb 17;7(2):e013537
pubmed: 28213598
Br J Psychiatry. 2002 May;180:461-4
pubmed: 11983645
Health Econ. 2004 Dec;13(12):1203-10
pubmed: 15386669
Cogn Behav Ther. 2020 May;49(3):242-255
pubmed: 31429639
Psychol Med. 2019 Sep;49(12):1937-1947
pubmed: 31179960
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Lancet. 2009 Aug 22;374(9690):628-34
pubmed: 19700005
Stat Med. 2005 Dec 30;24(24):3715-27
pubmed: 16320287
Br J Psychiatry. 2010 Oct;197(4):297-304
pubmed: 20884953
World Psychiatry. 2016 Oct;15(3):245-258
pubmed: 27717254
Contemp Clin Trials. 2012 Mar;33(2):312-9
pubmed: 22101205
Cogn Behav Ther. 2019 Nov;48(6):463-481
pubmed: 30507343
Health Econ. 2001 Dec;10(8):779-87
pubmed: 11747057
Qual Health Res. 2016 Nov;26(13):1753-1760
pubmed: 26613970
J Consult Clin Psychol. 2007 Jun;75(3):363-73
pubmed: 17563153
Behav Res Ther. 2013 Jan;51(1):37-45
pubmed: 23178677
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941

Auteurs

Debbie Tallon (D)

Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK. d.tallon@bristol.ac.uk.

Laura Thomas (L)

Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Sally Brabyn (S)

ARRC 208, Department of Health Sciences, University of York, York, YO10 5DF, UK.

Brian Chi Fung Ching (BCF)

UCL Division of Psychiatry, Maple House, 149 Tottenham Court Road, London, WIT 7BN, UK.

Jane Sungmin Hahn (JS)

UCL Division of Psychiatry, Maple House, 149 Tottenham Court Road, London, WIT 7BN, UK.

Berry Jude (B)

UCL Division of Psychiatry, Maple House, 149 Tottenham Court Road, London, WIT 7BN, UK.

Mekeda X Logan (M)

UCL Division of Psychiatry, Maple House, 149 Tottenham Court Road, London, WIT 7BN, UK.

Alex Burrage (A)

Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Fiona Fox (F)

Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Simon Gilbody (S)

Mental Health & Addiction Research Group, University of York & Hull York Medical School, York, UK.

Paul Lanham (P)

Public and Patient Involvement Representative, London, UK.

Glyn Lewis (G)

UCL Division of Psychiatry, Maple House, 149 Tottenham Court Road, London, WIT 7BN, UK.

Jinshuo Li (J)

Department of Health Sciences, Seebohm Rowntree Building, University of York, Heslington, York, YO10 5DD, UK.

Stephanie J MacNeill (SJ)

Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.

Irwin Nazareth (I)

Department of Primary Care & Population Health, University College London, Royal Free Site, Rowland Hill Street, London, NW3, UK.

Steve Parrott (S)

Department of Health Sciences, Seebohm Rowntree Building, University of York, Heslington, York, YO10 5DD, UK.

Tim J Peters (TJ)

Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS21 2LY, UK.

Roz Shafran (R)

Great Ormond Street Institute of Child Health London, University College London, London, WC1N 1EH, UK.

Katrina Turner (K)

Centre for Academic Primary Care, Bristol Medical School, Population Health Sciences, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Chris Williams (C)

Clarice Pears Building, University of Glasgow, 90 Byres Road, Glasgow, G12 8TA, UK.
Five Areas Ltd, 1 Aurora Avenue, Clydebank, G81 1BF, UK.

David Kessler (D)

Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Nicola Wiles (N)

Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH